Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Chubb
Merck
Dow
Farmers Insurance
Fish and Richardson
Fuji
Mallinckrodt
UBS
Cerilliant

Generated: December 10, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,901,385

« Back to Dashboard

Which drugs does patent 7,901,385 protect, and when does it expire?


Patent 7,901,385 protects SUMAVEL DOSEPRO and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 7,901,385

Title:Casing
Abstract:A casing (50) for an injection device (10) of the type having a safety device which prevents operation of the device (10), incorporating an actuator means (56) by which the safety means of the device (10) can be actuated to allow operation of the device (10). Also a casing (50) for a medicament container having an opening closed prior to use by a break-off tip (135), having relatively moveable first and second casing parts (51, 52), which on relative movement apply a breaking force to the break-off tip (135). A preferred embodiment includes both such features.
Inventor(s): Anderson; Gregor John McLennan (Ware, GB), Mitchell; John (London, GB)
Assignee: Zogenix, Inc. (Emeryville, CA)
Application Number:10/506,959
Patent Claim Types:
see list of patent claims
Use; Device; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Endo Ventures LtdSUMAVEL DOSEPROsumatriptan succinateINJECTABLE;SUBCUTANEOUS022239-001Jul 15, 2009BXRXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,901,385

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0206560.5Mar 20, 2002
PCT Information
PCT FiledMarch 18, 2003PCT Application Number:PCT/EP03/02876
PCT Publication Date:September 25, 2003PCT Publication Number: WO03/077973

Non-Orange Book Patents for Patent: 7,901,385

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,267,903Casing► Subscribe
9,259,534Casing► Subscribe
8,715,259Casing► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,901,385

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4504688► Subscribe
Japan2005530522► Subscribe
United Kingdom0206560► Subscribe
Spain2290443► Subscribe
European Patent Office1487517► Subscribe
Germany60315429► Subscribe
Canada2479316► Subscribe
Australia2003219086► Subscribe
World Intellectual Property Organization (WIPO)03077973► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
US Army
McKesson
Merck
AstraZeneca
Citi
Moodys
Baxter
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot